• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page


Working in Urology/GYN 2024

Quote

anonymous

Guest
Hello

what is it like working in the urology gynecology space in 2024? I’ve been told OTE is 240k. Does quota seem feasible? How do you stack up among the competitors. What are your biggest challenges?


Thanks
 




Every territory is different, typically those in the largest markets do better financially.
This Division has encountered some difficulty as virtually all of the Divisions have over the pandemic but our best days are ahead of us. I have seen a number of recent successes that lead me to believe this year will be reflective of the pre-pandemic time. Gotta case to get to.
 




anonymous said:
Every territory is different, typically those in the largest markets do better financially.
This Division has encountered some difficulty as virtually all of the Divisions have over the pandemic but our best days are ahead of us. I have seen a number of recent successes that lead me to believe this year will be reflective of the pre-pandemic time. Gotta case to get to.
Click to expand...


Awesome thanks. Do you feel as if Storz is a competitor in the market place? My current company is dying as far as innovation Goes. Do you feel like quota is attainable?
 












Storz URO is a dumpster fire. More recalls and rolling back orders than the rest of the company combined. That said, you can definitely do well in a solid territory with deep legacy business.
 




Top Bottom
Back
Quote